Roche lymphoma drug drives high remission rate, longer survival-study - Reuters

Roche lymphoma drug drives high remission rate, longer survival-study Reuters Dec 10 (Reuters) - An experimental Roche Holding AG drug, added to standard therapy, led to a far higher rate of remission and helped patients with an advanced, aggressive blood cancer live significantly longer than the standard treatment alone ... Phase II Data Showed Genentech's Investigational Polatuzumab Vedotin Plus Bendamustine and Rituxan (BR ...Business Wire (press release) all 2 news articles »

from Health - Google News http://ift.tt/2AJ7gZa